![Douglas W. Wilmore](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Douglas W. Wilmore
Keine laufenden Positionen mehr
Karriereverlauf von Douglas W. Wilmore
Ehemalige bekannte Positionen von Douglas W. Wilmore
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
EMI Holding, Inc.
![]() EMI Holding, Inc. Pharmaceuticals: MajorHealth Technology EMI Holding, Inc. discovers, develops, and commercializes treatments and therapies for rare diseases. The firm also engages in the marketing and sale of NutreStore L-glutamine powder for oral solution, a treatment for short bowel syndrome and the sale of L-glutamine as a nutritional supplement under the brand name AminoPure. The company was founded by Yutaka Niihara in 1987 and is headquartered in Torrance, CA. | Direktor/Vorstandsmitglied | 03.05.2011 | 01.09.2011 |
Independent Dir/Board Member | 14.07.2011 | 01.09.2011 | |
Emmaus Medical, Inc.
![]() Emmaus Medical, Inc. BiotechnologyHealth Technology Emmaus Medical, Inc. engages in the discovery, development and commercialization of treatments and therapies for rare diseases. Its current business is the late-stage development presently in Phase III clinical trials with the FDA of the amino acid L-glutamine as a prescription drug for the treatment of Sickle Cell Disease. The company was founded on December 20, 2000 and is headquartered in Torrance, CA. | Direktor/Vorstandsmitglied | 08.02.2010 | - |
Ausbildung von Douglas W. Wilmore
University of Kansas | Undergraduate Degree |
Washburn University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Director/Board Member | 2 |
Undergraduate Degree | 2 |
Independent Dir/Board Member | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Emmaus Medical, Inc.
![]() Emmaus Medical, Inc. BiotechnologyHealth Technology Emmaus Medical, Inc. engages in the discovery, development and commercialization of treatments and therapies for rare diseases. Its current business is the late-stage development presently in Phase III clinical trials with the FDA of the amino acid L-glutamine as a prescription drug for the treatment of Sickle Cell Disease. The company was founded on December 20, 2000 and is headquartered in Torrance, CA. | Health Technology |
EMI Holding, Inc.
![]() EMI Holding, Inc. Pharmaceuticals: MajorHealth Technology EMI Holding, Inc. discovers, develops, and commercializes treatments and therapies for rare diseases. The firm also engages in the marketing and sale of NutreStore L-glutamine powder for oral solution, a treatment for short bowel syndrome and the sale of L-glutamine as a nutritional supplement under the brand name AminoPure. The company was founded by Yutaka Niihara in 1987 and is headquartered in Torrance, CA. | Health Technology |
- Börse
- Insiders
- Douglas W. Wilmore
- Erfahrung